INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

INOVIO (NASDAQ: INO), a biotechnology firm focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced that Jacqueline Shea, Ph.D., CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:40 AM ET.

Dr. Shea and the management team will engage in one-on-one meetings with investors. A webcast of the presentation will be available on the INOVIO Investor Relations Events page, with a replay accessible for 90 days post-event. INOVIO's innovative approach includes using the CELLECTRA® device to generate immune responses against targeted health threats.

News Market Reaction – INO

+1.54%

+1.54% Session move

In the trading session that priced this news, INO gained 1.54%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.

Oppenheimer 33rd Annual Healthcare Conference
Date: Monday, March 13, 2023
Time: 10:40 AM ET
Format: Fireside Chat

During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-301761773.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When is INOVIO's presentation at the Oppenheimer 33rd Annual Healthcare Conference?

INOVIO's presentation at the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, at 10:40 AM ET.

Who will represent INOVIO at the Oppenheimer Conference?

Jacqueline Shea, Ph.D., CEO, will represent INOVIO at the Oppenheimer 33rd Annual Healthcare Conference.

Will there be a webcast for INOVIO's presentation?

Yes, a webcast of INOVIO's presentation will be available on their Investor Relations Events page.

How long will the webcast of INOVIO's presentation be available?

The webcast of INOVIO's presentation will be available for 90 days following the event.

What is INOVIO's focus in biotechnology?

INOVIO focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases.